Merck (NYSE: MRK) and Eisai announced that their Phase 3 LITESPARK-012 trial evaluating combination treatments for advanced renal cell carcinoma ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE